Department of Pharmacy Practice, University of Findlay College of Pharmacy, Findlay, Ohio, USA.
Pharmacy Department, Mercy Health-St. Anne Hospital, Toledo, Ohio, USA.
J Clin Pharmacol. 2021 Feb;61(2):211-223. doi: 10.1002/jcph.1727. Epub 2020 Aug 26.
Published vancomycin dosing recommendations for patients receiving maintenance hemodialysis were not designed to meet newly recommended 24-hour area under the curve/minimum inhibitory concentration (AUC /MIC) pharmacokinetic/pharmacodynamic targets. The aims of this study were to predict pharmacokinetic/pharmacodynamic target attainment rates with a commonly used vancomycin regimen and to design a new dosing scheme incorporating therapeutic drug monitoring (TDM) to maximize target attainment in patients receiving vancomycin and hemodialysis with high- or low-flux hemodialyzers. Vancomycin pharmacokinetic- and dialysis-specific parameters were incorporated into Monte Carlo simulations (MCS). A commonly used vancomycin regimen was modeled to determine its likelihood of attaining AUC /MIC targets for 1 week of thrice-weekly hemodialysis treatments. MCS was then used to develop optimal initial vancomycin dosing for patients receiving intradialytic or postdialytic vancomycin administration with either high- or low-flux hemodialyzers. Finally, a new MCS model incorporating TDM was built to further optimize the probability of pharmacokinetic/pharmacodynamic target attainment. Traditional vancomycin dosing methods are unlikely to meet AUC /MIC targets. Vancomycin doses necessary to attain AUC /MIC targets are significantly influenced by hemodialyzer permeability and whether vancomycin is administered intradialytically or after hemodialysis. Depending on dialyzer type and whether vancomycin is administered during or after hemodialysis, loading doses of 25 to 35 mg/kg followed by maintenance doses of 7.5 to 15 mg/kg are necessary to reach minimum AUC /MIC targets in 90% of virtual patients. For a 3-day interdialytic period, a 30% higher maintenance dose is required to maintain target attainment. Dosing based on a single vancomycin serum concentration obtained prior to the second dialysis session greatly enhances the probability of target attainment.
用于接受维持性血液透析患者的万古霉素给药推荐方案并非专门设计以满足新推荐的 24 小时 AUC/MIC(药代动力学/药效学)目标。本研究的目的是预测使用常用万古霉素方案的药代动力学/药效学目标达标率,并设计一种新的给药方案,纳入治疗药物监测(TDM),以最大限度地提高接受万古霉素治疗且使用高通量或低通量血液透析器进行血液透析的患者的目标达标率。将万古霉素药代动力学和透析特异性参数纳入蒙特卡罗模拟(MCS)中。模拟常用万古霉素方案,以确定其在每周三次血液透析治疗 1 周时达到 AUC/MIC 目标的可能性。然后使用 MCS 为接受透析内或透析后万古霉素给药的患者开发最佳初始万古霉素剂量,无论使用高通量还是低通量血液透析器。最后,构建了一个新的纳入 TDM 的 MCS 模型,以进一步优化药代动力学/药效学目标达标率的概率。传统的万古霉素给药方法不太可能达到 AUC/MIC 目标。达到 AUC/MIC 目标所需的万古霉素剂量受血液透析器通透性以及万古霉素是在透析内还是透析后给药的显著影响。根据透析器类型以及万古霉素是在透析期间还是之后给药,需要给予 25 至 35mg/kg 的负荷剂量,然后给予 7.5 至 15mg/kg 的维持剂量,才能使 90%的虚拟患者达到最低 AUC/MIC 目标。对于 3 天的无透析间隔期,需要增加 30%的维持剂量才能维持目标达标率。基于第二次透析前获得的单次万古霉素血清浓度进行给药可极大地提高目标达标率。